The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
Antibiotic resistance can affect anyone, anywhere
Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. It is already associated with nearly 5 million deaths per year, making it one of the world’s biggest killers.
A global crisis of antibiotic resistance
Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.
Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.
Low- and middle-income countries, and certain population groups like women and children are hit hardest.
If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.
GARDP is acting now to counter drug resistance and save lives
GARDP is working to deliver on its “5by2025” initiative and to expand its portfolio with new treatments for bacterial infections that pose the greatest threat to human health.
GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.
We engage with all key stakeholders from the get-go to coordinate efforts in the antibiotic pipeline to develop an ecosystem of antibiotic R&D and access.
